NDA 220442 · Shionogi
Xocova
Ensitrelvir · Oral
NovelCDER novel approval, May 29, 2026: To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 29, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
3 Phase 3, 1 recruiting
FAERS reports
18
8 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 3, 2026.
XOCOVA is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19. XOCOVA, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro : also referred to as 3CL pro or nsp5 protease) inhibitor, is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID‑19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19. ( 1 )
Mechanism: Ensitrelvir is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- XOCOVA · ENSITRELVIR 125MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ensitrelvir" as an intervention, any sponsor and status, largest first.
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 InfectionPivotal-lookingCompleted
ShionogiIndustry
NCT05897541 · 3,701 participants · Start Jun 9, 2023 · Primary completion Aug 30, 2024
Drug: S-217622; Placebo · For: SARS-CoV-2 Infection
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 178 sites in all
- A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19Pivotal-lookingCompleted
ShionogiIndustry
NCT05305547 · 2,093 participants · Start Aug 3, 2022 · Primary completion Jan 7, 2024
Drug: S-217622; Placebo · For: SARS-CoV-2 Infection
Sites: Guntersville, Alabama; Tempe, Arizona; Tucson, Arizona · 196 sites in all
- Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)Pivotal-lookingTerminated
University of MinnesotaAcademic, hospital or other
NCT05605093 · 602 participants · Start Dec 23, 2022 · Primary completion Oct 28, 2025
Drug: Shionogi Protease Inhibitor (S-217622); placebo · For: COVID-19
Sites: Birmingham, Alabama; Tucson, Arizona; Fresno, California · 187 sites in all
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVIDActive, not recruiting
Timothy HenrichAcademic, hospital or other
NCT06161688 · 40 participants · Start Apr 9, 2024 · Primary completion Dec 20, 2024
Drug: Ensitrelvir · For: Long COVID; Post Acute Sequelae of COVID-19; Post-Acute COVID-19
Sites: San Francisco, California
ShionogiIndustry
NCT05363215 · 32 participants · Start Aug 10, 2022 · Primary completion Apr 12, 2023
Drug: S-217622 · For: Renal Impairment
Sites: Miami, Florida; Orlando, Florida; Saint Paul, Minnesota · 4 sites in all
ShionogiIndustry
NCT05409911 · 25 participants · Start Sep 13, 2022 · Primary completion Apr 25, 2023
Drug: S-217622 · For: Hepatic Impairment
Sites: Miami, Florida; Orlando, Florida; Saint Paul, Minnesota · 4 sites in all
ShionogiIndustry
NCT06775730 · 24 participants · Start Dec 30, 2024 · Primary completion Apr 3, 2025
Drug: Ensitrelvir · For: Healthy Adult Female Participants
Sites: Glendale, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction8
- product use in unapproved indication7
- drug half-life increased4
- immunosuppressant drug level increased4
- covid-193
- covid-19 pneumonia3
- drug clearance decreased3
- blood creatinine increased2
- drug ineffective for unapproved indication2
- drug level increased2
- off label use2
- pneumonia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 6 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
Hayden FG, Shinkai M, Clark TW, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
Yotsuyanagi H, Ohmagari N, Doi Y, et al. · JAMA Netw Open 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.
Luetkemeyer AF, Chew KW, Lacey S, et al. · Clin Infect Dis 2025 · Clinical Trial, Phase III, Multicenter Study
- A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Yotsuyanagi H, Ohmagari N, Doi Y, et al. · Medicine (Baltimore) 2023 · Randomized Controlled Trial, Multicenter Study
- Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK, Jittamala P, Wongnak P, et al. · Lancet Infect Dis 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Ul Haq MZ, Ashraf S, Shah MSU, et al. · Infection 2025 · Systematic Review, Meta-Analysis
Sponsor: Shionogi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.